In a previous essay, I touched on medical progress with regard to research being carried out in Israel by hundreds of biotech and biomedical startup companies sparse throughout the country.
Today, I continue with other interesting ideas that may help us live as long as trees and look years younger. In recent years, there has been an increase in the number of patents with regard to medical devices and diagnostics companies in Israel and abroad which have already completed successful proof of concept studies in animal models and are embarking on first clinical studies in humans.
One case in point is centered on cosmetic tissue augmentation, wound healing and tissue regeneration. The technology is based on a novel adhesive peptide for tissue engineering. The foundation of these technologies is based on the biological activity of fibrin, a protein responsible for blood coagulation, which the inventors adapted for multiple uses for cell culturing and tissue engineering. Moreover, it is estimated that over 10,000 patients died within the past five years waiting for an organ transplant. Tissue engineering could in the future replace organs and avoid the hazards associated with organ transplantation.
Major advances are being done with regard to treating Lupus disease which is a dreadful disease with no cure that turns the body’s defenses against the body itself and affects organ systems, skin, joints and internal organs. Around 400,000 Americans suffer from lupus. A company in Israel is developing a drug-device column which selectively removes from circulation more than 90% of the antibodies in the blood associated with this disease. This innovative method represents a breakthrough in the treatment of lupus, since until now, there has been no treatment for this ailment and the standard care has been based on the use of steroids and chemotherapy with serious side-effects.
Another exciting development is the advent of novel diagnostic tools for breast and colon cancer metastasis, diagnosis and prognosis. This novel diagnostic method is capable of evaluating the state of cancer progression, and most importantly, the efficacy of treatment with a single blood test.
In the advent of a stroke, heart attack and deep vein thrombosis, hospitals use what is called thrombolytic agents or anticoagulants in order to dissolve a clot and reopen an artery or vein. However, these agents in existence today cause severe side effects including damage to blood vessels and internal hemorrhage. We have already witnessed what happened to the former Prime Minister Sharon after his first stroke and treatment with anticoagulants. Fortunately, a company in Israel is developing safer and more efficient anticoagulant drugs for the treatment of stroke, heart attack and related indications.
Medical technological advances sprout each day and with the advent of stem cell therapy, I posit that within the next decade, serious diseases such as cancer will be treated and conquered with single injections rather than the traumatic and uncertain methodology used today.